((自动化翻译由路透提供，请见免责声明 ))
10月16日 - ** Novavax 股价在收盘前下跌 25%，至 9.43 美元
** 该公司称美国食品和药物管理局已暂停其流感疫苗和COVID-流感联合疫苗的临床试验申请
** NVAX称，临床搁置的原因是有报告称，2023年1月在美国境外接受注射的一名试验参与者出现了严重的运动神经病变并发症，即运动神经受损。
** 该公司表示，NVAX之前的COVID-19和流感试验数据未显示运动神经病变信号
** NVAX公司称，中期试验已于2023年7月完成，参与者于2024年9月报告了并发症。
** 该公司表示，将尽快满足FDA提供更多信息的要求
** 截至上一交易日收盘，NVAX股价已上涨近三倍。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.